Deep Brain Stimulation Devices Market By Application (Parkinson’s Disease, Essential Tremor), Product (Single Channel, Dual-Channel) - Partner & Customer Ecosystem (Product Services, Proposition & Key Features) Competitive Index & Regional Footprints by MarketDigits - Forecast 2024 – 2032

The Global Market for deep brain stimulation devices, which was valued at USD 1.05 billion in 2021, is expected to experience a compound annual growth rate (CAGR) of 9.8% from 2023 to 2030. Market growth will be driven by the increasing number of patients suffering from involuntary movements associated with Parkinson's disease, dystonia, and multiple sclerosis. The demand for minimally invasive techniques, which lead to improved patient outcomes, is also a significant driver for market growth. Furthermore, the adoption of telehealth consultations and eHealth apps during the COVID-19 pandemic to monitor patients with Parkinson's disease is expected to further support the growth of the deep brain stimulation (DBS) devices market.

However, the outbreak of COVID-19 has had a negative impact on the market. It has directly affected demand and production, disrupted the supply chain, and imposed financial burdens on firms. Brain surgeries have been postponed or canceled during this period to prevent the spread of the virus. In severely affected countries, such as the U.S., Russia, India, Brazil, France, the U.K., Italy, and Spain, neurosurgical operations declined by 55%.

Manufacturers have faced challenges in serving their surgeon customers due to restricted access to hospitals or changes in access regulations. Consequently, procedural volumes decreased in 2020, hindering market growth. However, the increased use of teleconsultancy for follow-up and routine check-ups of Parkinson's disease patients during the pandemic has positively influenced market growth. These trends are expected to significantly impact the adoption of DBS in the coming years.

The market is being driven by the rising prevalence of neurological disorders such as Parkinson's disease, essential tremor, dystonia, and epilepsy. According to the World Health Organization (WHO), neurological diseases contribute significantly to the global disease burden, causing a substantial number of deaths worldwide, particularly in developed and low- to middle-income countries. The urgent need for long-term solutions and the awareness of the high disease burden have increased the demand for deep brain stimulators as an alternative therapy, thereby fueling market growth.

Moreover, technological advancements in DBS technologies present growth opportunities in the market. These advancements include robot-assisted implantation, improved microelectrode designs, multi-target stimulation, rechargeable implantable pulse generators, and personalized directed programming. These innovations have led to reduced adverse effects and improved efficacy and symptomatic relief for patients with Parkinson's disease compared to traditional methods. Notably, Abbott's Infinity Deep Brain Stimulation System is an example of a technologically enhanced DBS that offers efficient and personalized therapy management with a lower risk of adverse effects.

Countries like the United States and Canada have observed a high prevalence rate of movement and psychiatric disorders, along with a growing elderly population. Parkinson's disease symptoms, for instance, commonly manifest around the age of 60, making the geriatric population particularly susceptible to these disorders. Furthermore, the increasing number of FDA approvals for deep brain stimulation devices in clinical applications such as tremors, severe obsessive-compulsive disorders, and dystonia is driving market growth. For instance, NeuroPace, Inc. received FDA approval in March 2020 for MRI labeling of its RNS System. These factors contribute to the growing demand for DBS devices in these countries.

Moreover, the need for a targeted therapy approach is being propelled by severe adverse effects and drug interactions resulting from drug absorption by non-targeted sites. This factor further drives the demand for deep brain stimulation (DBS) devices. While certain drugs can offer significant improvements in motor function, they may also lead to adverse effects, especially as the disease progresses. Long-term complications such as hallucinations, dyskinesia, neurotoxic effects, and severe metabolic changes can arise from the continuous administration of drugs like levodopa. Consequently, these adverse effects highlight the clinical necessity to incorporate alternatives based on targeted therapy approaches, including the use of deep brain stimulators. This, in turn, stimulates market growth during the forecast period.

Product Insights
The market is divided into single-channel and dual-channel deep brain stimulation devices based on the product. Currently, the dual-channel segment dominates the market with a 57.12% share in 2021 due to its higher adoption in surgical procedures. Dual-channel devices are considered safe and effective for surgical procedures, contributing to their widespread use in hospitals. The high prevalence of disabling neurological diseases, the increasing number of surgical procedures for Parkinson's disease, and the growing adoption of dual-channel DBS devices by hospitals drive the growth of this segment. Furthermore, technological advancements and new product launches further propel segment growth. For example, in January 2020, Abbott's Infinity DBS system received FDA approval for the expanded indication of treating Parkinson's disease, allowing for targeting of the specific brain area called the internal Globus Pallidus (GPi) associated with Parkinson's disease symptoms.

However, the single-channel deep brain stimulation device segment is projected to grow at the highest compound annual growth rate (CAGR) of 10.0% from 2023 to 2030. Healthcare professionals believe that single-channel devices offer more programming options to neurologists, leading to increased preference for these devices. The geriatric population is particularly susceptible to neurological diseases, as highlighted by the Parkinson's Foundation. The World Ageing 2019 report estimated a global population of about 703 million people aged 65 years or older in 2019. Therefore, the increasing geriatric population, growing awareness of neurological diseases among patients, and preference among healthcare professionals are expected to drive the growth of the single-channel segment.

Application Insights
Based on application, the Parkinson's disease segment dominates the market with a 65.13% share in 2021. This is attributed to the increasing number of FDA approvals for deep brain stimulation therapies and the high prevalence of Parkinson's disease worldwide. In December 2017, Boston Scientific Corporation received FDA approval for the Vercise deep brain stimulation device system for the treatment of Parkinson's disease. According to the Parkinson's Foundation, approximately 60,000 people are diagnosed with Parkinson's disease in the U.S. each year, which is expected to drive the growth of this segment in the future.

However, the epilepsy segment is projected to experience the highest compound annual growth rate (CAGR) of 16.1% from 2023 to 2030. The increasing awareness of advanced treatment options for epilepsy and the development of healthcare infrastructure are expected to drive segment growth in the coming years. According to the World Health Organization (WHO), approximately 50 million people worldwide suffer from epilepsy, making it one of the most common neurological diseases. Deep brain stimulation (DBS) is used in epilepsy cases where medication has a low therapeutic response in controlling seizures or when surgeries have reduced success rates. These factors contribute to the growth of the epilepsy segment.

End-Use Insights
Hospitals currently dominate the overall market growth, accounting for a 51.88% share in 2021. The growth of this segment can be attributed to the increasing number of DBS surgeries performed in hospitals and the rising prevalence of conditions like Parkinson's disease and essential tremor. Additionally, the availability of technologically advanced DBS devices and favorable reimbursement policies further contribute to the growth of the hospital market. For example, Medtronic offers comprehensive services to ensure coverage and payment for various DBS devices.

Furthermore, hospitals are advancing in terms of technology, utilizing advanced devices that simplify treatment procedures and provide better, faster, and more accurate results. Specialty hospitals with professional neurologists play a significant role in diagnosing and treating neurological disorders, including Parkinson's disease, using advanced equipment.

However, the Ambulatory Surgical Centers (ASC) segment is expected to grow at the highest compound annual growth rate (CAGR) of 10.3% from 2023 to 2030. This can be attributed to the lower cost of procedures compared to hospitals, convenient patient access, reduced waiting times, and lower infection rates compared to neurology clinics and hospitals. A study conducted by Advancing Surgical Care showed that 92% of patients were satisfied with the medical care and service provided in ASCs, further contributing to segment growth. Moreover, most neurosurgeries can now be performed at ASCs, as these centers offer advanced and less invasive surgical procedures. The segment's growth is mainly driven by shorter procedure times and ongoing advancements in minimally invasive surgical techniques.

Regional Insights
North America currently dominates the market with a 51.59% share in 2021. This is attributed to increased government funding and initiatives aimed at raising awareness about Parkinson's disease (PD), which drive the demand for deep brain stimulators. For example, the Parkinson's Foundation funded over 40 research projects for PD in 2015. Additionally, the growing number of FDA approvals for deep brain stimulators for PD treatment contributes to market growth. In October 2016, St. Jude Medical received FDA approval for its St. Jude Medical Infinity DBS and directional lead technology for PD treatment.

Moreover, the market growth in this region can be attributed to the presence of major competitors, sophisticated healthcare infrastructure, and supportive government initiatives. For example, the National Institute of Neurological Disorders and Stroke (NINDS) supports research activities related to DBS to determine its safety and effectiveness in treating Parkinson's disease (PD).

However, Asia Pacific is expected to emerge as the leading market from 2023 to 2030. This can be attributed to the increasing prevalence of neurodegenerative disorders and the growing demand for effective and long-term solutions in the region. Rising awareness about treatment options for neurological diseases and improvements in the clinical development framework in emerging economies are expected to drive market growth. Additionally, high growth opportunities in countries like Japan, China, and India are likely to contribute to market expansion. The establishment of organizations such as the Asia-Pacific Centre for Neuromodulation (APCN), which conducts research and promotes awareness about the benefits of deep brain stimulation, is anticipated to further boost regional growth.

Key Companies & Market Share Insights
Key players in the industry are focusing on product launches, technological advancements, and growth strategies like mergers and acquisitions to strengthen their position in the market. For example, in September 2019, LivaNova, in collaboration with MicroPort Scientific, received FDA China approval for RegaTM pacemakers. These pacemakers are the smallest in the Chinese cardiac rhythm management market, and the approval will enhance the company's local presence and expand its footprint in China.

Emerging players such as NeuroPace, Inc., and Aleva Neurotherapeutics SA, are considered innovators in the market. Products offered by these competitors have a good price-performance proposition, competitive functionality, and are technologically advanced. These players are focusing on product commercialization activities as well as fundraising activities to support the R&D growth. For instance, in October 2017, NeuroPace, Inc. closed a USD 74 million funding round initiated by OrbiMed Advisors and KCK Groups. The funding will support the company’s ongoing efforts for rapid expansion and commercialization of its FDA-approved DBS product- the NeuroPace RNS system. Some of the key players operating in the global deep brain stimulation devices market include:
• Abbott (St. Jude Medical)
• Medtronic
• Boston Scientific Corporation
• Aleva Neurotherapeutics S.A.
• Nexstim
• LivaNova PLC
• Neuropace Inc.

Segments Covered in the Report
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global deep brain stimulation devices market report based on product, application, end-use, and region:
• Product Outlook (Revenue USD Million, 2018 - 2030)
• Single Channel
• Dual Channel

Application Outlook (Revenue USD Million, 2018 - 2030)
• Pain Management
• Epilepsy
• Essential Tremor
• Obsessive-Compulsive Disorder (OCD)
• Depression
• Dystonia
• Parkinson’s Disease
• Others

End Use Outlook (Revenue USD Million, 2018 - 2030)
• Hospitals
• Neurology Clinics
• Ambulatory Surgical Centers
• Research Centers

Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
o U.S.
o Canada
• Europe
o Germany
o U.K.
o France
o Italy
o Spain
• Asia Pacific
o Japan
o China
o India
o Australia
o South Korea
• Latin America
o Brazil
o Mexico
o Argentina
o Colombia
• Middle East and Africa (MEA)
o South Africa
o Saudi Arabia
o UAE